Marksans Pharma Limited Q2 FY26 Concall Decoded: From Q1 hangover to Q2 comeback – tariffs panicked, margins flexed, confidence restored

1. Opening Hook

After a Q1 that felt like a Monday morning without coffee, Marksans Pharma walked into Q2 and casually reminded everyone why it’s still one of the sharper operators in Indian pharma.

Tariff paranoia froze decisions, UK pricing played villain, and inventory ballooned like it was prepping for apocalypse season. Then Q2 happened. Revenue bounced back, margins snapped higher, and management suddenly sounded like they slept well again.

US demand picked up, approvals kept flowing, and the Teva Goa plant passed the FDA with zero observations—because nothing boosts confidence like regulators finding nothing to complain about.

If Q1 was the panic episode, Q2 was the calm explanation.
Stick around—because the real story here is scale, patience, and where ₹5,000 crore dreams actually come from.

2. At a Glance

Revenue ₹720 Cr (+12% YoY) – Recovery mode activated after a forgettable Q1.
QoQ growth +16% – Demand came back, excuses left the room.
EBITDA ₹145 Cr (+44% QoQ) – Operating leverage finally stretching its legs.
PAT ₹99 Cr (+70% QoQ) – Profits woke up aggressively.
Cash ₹666 Cr, Debt-free – Balance sheet flex without chest-thumping.

3. Management’s Key Commentary (Decoded)

“Q2 has been a strong quarter reflecting recovery from a softer Q1.”
(Translation: Q1 was bad. We’re not pretending otherwise.) 😏

“US performed robustly despite micro headwinds.”
(Translation: Tariffs scared everyone, but orders still came.)

“Price erosion remains low single digit.”
(Translation: Finally, not a knife fight.)

“UK revenues to double over 5–7 years.”
(Translation: Pain now, payoff later—trust the filings.)

“FDA inspection completed with zero Form 483.”
(Translation: Compliance gold medal.) 🏅

“CARE upgraded us to AA-.”
(Translation: Even rating agencies stopped worrying.)

“We remain confident of sustaining momentum.”
(Translation: This wasn’t a fluke quarter.) 😌

4. Numbers Decoded

Source table

Metric	Q2 FY26	Q2 FY25	What It Really Says
Revenue	₹720 Cr	₹642 Cr	Core markets firing again
EBITDA Margin	20.1%	21.2%	QoQ

To Read Full 16 Point

Continue reading with a premium membership.